CATALYST DOSSIER · UPDATED 2026-11-12
$MMED
biotech · convergence -5 · conviction WATCH
Price & Live Quote Loading live quote & chart…
Practice trade tools Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.
Paper trade unavailable: missing risk-bounded frame
Reference only. Not financial advice. No brokerage order is placed.
Why $MMED?
Quantitative
Forward EPS estimate : $$0.10 (vs $N/A last yr YoY)
Market cap : $4,884,234,800
Convergence score : -5 (9 signals firing YoY)
Catalysts
Multi-spoke convergence : 9 convergent signals fired: earnings, sc13d, xbrl_ni, ftd, audit_extras
Risks
Position-sizing discipline : Conviction WATCH (-5 score) — size accordingly; no specific catalyst-fade risk flagged
Bear case
Earnings binary : Print-day moves can swing ±15% — gap risk both directions
Sympathy basket (cerebro)
NVDA via semis r=+0.97 sympathetic (score 14)
AMAT via semis r=+0.97 sympathetic (score 6)
NIQ via tech r=+0.96 sympathetic (score 18)
ENS via tech r=+0.96 sympathetic (score 14)
WEX via industrials r=+0.91 sympathetic (score 14)
KBR via industrials r=+0.91 sympathetic (score 12)
Signals Firing
earnings sc13d xbrl_ni ftd audit_extras auto_macro_adp_payrolls auto_macro_banrep_colombia auto_macro_bls_employment auto_macro_durable_goods
Pick Track Record Date List Next-day max run Next-day close Hit +2%? 2026-09-16 sec_top_gappers +1.2% -1.7% — 2026-09-16 sec_top_moat_emerging +1.2% -1.7% — 2026-09-15 sec_top_gappers +6.1% +1.8% ✓ hit 2026-09-15 sec_top_moat_emerging +6.1% +1.8% ✓ hit 2026-09-14 sec_top_gappers +2.5% +0.2% ✓ hit 2026-09-14 sec_top_moat_emerging +2.5% +0.2% ✓ hit
Lifetime: 4/6 wins · hit-rate 66.7% on +2% intraday
Sympathy Basket NVDA via semis · score 14 AMAT via semis · score 6 NIQ via tech · score 18 ENS via tech · score 14 WEX via industrials · score 14 KBR via industrials · score 12
Earnings Catalyst No recent earnings event.
Generate full earnings report
Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks
and its losses — see the
trust report and
methodology .
Not financial advice. Confirm independently before trading.